Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
äŒæ¥ã³ãŒãMIRM
äŒç€ŸåMirum Pharmaceuticals Inc
äžå Žæ¥Jul 18, 2019
æé«çµå¶è²¬ä»»è
ãCEOãPeetz (Christopher)
åŸæ¥å¡æ°322
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 18
æ¬ç€Ÿæåšå°989 East Hillsdale Boulevard, Suite 300
éœåžFOSTER CITY
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94404
é»è©±çªå·16506674085
ãŠã§ããµã€ãhttps://mirumpharma.com/
äŒæ¥ã³ãŒãMIRM
äžå Žæ¥Jul 18, 2019
æé«çµå¶è²¬ä»»è
ãCEOãPeetz (Christopher)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã